PLSE
PULSE BIOSCIENCES, INC.
NASDAQ · Healthcare · Medical - Instruments & Supplies · US
$54.41
+4.23%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$52.96
From 52W high−1.93%
Volume95647.00
Market cap$3.88B
P/E (TTM)—
P/S (TTM)3274.8x
Div yield—
Key dataNov 4, 2026
Open
$52.96
From 52W high
−1.93%
Volume
95647.00
Market cap
$3.88B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−47.6x
P/E (TTM)
—
RSI (14)
58.0
MomentumView details →
1D Return
+4.23%
YTD Return
+296.65%
SummaryUpdated Jun 1, 2026
Pulse Biosciences, Inc. (NASDAQ:PLSE) is a bioelectric medicine company founded in 2014 and headquartered in Hayward, California. Originally incorporated as Electroblate, Inc., the company changed its name to Pulse Biosciences in December 2015 and went public in May 2016. The company has undergone significant strategic evolution, initially focusing on dermatological applications before pivoting to cardiac and soft tissue ablation markets. Pulse Biosciences is currently in the clinical development stage, advancing multiple medical devices based on its proprietary nanosecond Pulsed Field Ablation (nsPFA) technology across three primary therapeutic areas.
Similar companies
Latest newsMore news →
PULSE BIOSCIENCES, INC. announced it will report third-quarter 2026 business updates and financial results after market close on November 5, 2026, and hold a conference call at 1:30 p.m. PT / 4:30 p.m. ET.13d agoPulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center covering use of its nPulse Vybrance Percutaneous Electrode System and a clinical collaboration.21d ago